At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Puerarin, Placebodrug
Likely dose
Puerarin, Placebo 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Puerarin (NPI-031G) Effects on Alcohol Drinking - A Natural Settings Study
In Brief
A Phase 2 clinical trial evaluating Puerarin, Placebo for Alcohol Abuse. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This research is designed to assess the impact of pretreatment with puerarin (NPI-031G), a major ingredient in the plant kudzu, on alcohol drinking. Hypothesis: Short-term treatment with this compound will reduce alcohol self-administration in a simulated natural settings laboratory.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Abuse
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMar 2009
Primary CompletionMar 2011
Study CompletionJul 2011
TodayJul 2026
First PostedMar 3, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.3 years ago
Interventions
Puerarin, Placebodrug
400 mg, three times a day for 7 days